← All trials
NCT00123097
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2005
- Primary completion
- Aug 31, 2009
- Completion date
- Aug 31, 2009
- First posted
- Jul 22, 2005
- Last posted
- Apr 7, 2017
- Enrollment
- 42
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of LouisvilleLead sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)Collaborator
- University of TorontoOverall official - principal investigator
- University of LouisvilleReponsible party - principal investigator
- University of LouisvilleSponsor investigator
- University of TorontoOfficial
- University of LouisvilleOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.